Science
Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit
In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to include millions of people with no memory complaints.
Those with normal cognition who test positive for elevated levels of certain proteins that have been tied to Alzheimer’s — but not proven to cause the disease — would be diagnosed as having Alzheimer’s Stage 1, the panel members explained.
Even before the presentation ended, attendees in the packed hall were lining up behind microphones to ask questions, according to video of the event.
“I’m troubled by this,” Dr. Andrea Bozoki, a University of North Carolina neurologist, told the panel. “You are taking a bunch of people who may never develop dementia or even cognitive impairment and you’re calling them Stage 1. That doesn’t seem to fit.”
Under the proposal, tens of millions of Americans with normal cognition would test positive for abnormal levels of amyloid or tau, the two proteins the tests look for, and the majority of them may never be diagnosed with dementia, studies suggest. A 60-year-old man who tests positive, for example, is estimated to have a 23% risk of developing dementia in his lifetime.
Criticism of the plan has intensified since it was unveiled in July at the international conference attended by 11,000 doctors and scientists. But the panel, organized by the nonprofit Alzheimer’s Assn., is continuing its push to extend the diagnosis to people who have no problem recalling events or what day it is — and convince skeptics that Alzheimer’s symptoms aren’t necessary to have the disease.
Panel members argue that the earlier patients get help, the more effective it might be. The availability of new drugs for patients with early Alzheimer’s symptoms has spurred them into action now, they say.
The plan could be approved by the panel and published in a medical journal early this year, association officials said. Such a move is likely to be influential: A similar proposal in 2018 that was put forth to help guide research on experimental Alzheimer’s medications was quickly adopted by the Food and Drug Administration and is frequently cited by doctors, scientists and health insurers.
Standing to benefit are the pharmaceutical and medical testing companies who employ seven members of the 20-person panel. At least seven more members of the panel are academics who receive money from those companies for consulting or research. Panelists reached by The Times said the funding did not influence their decisions.
Four other scientists who are outside advisors to the panel are executives from Eisai and Biogen, the makers of two new medicines for Alzheimer’s patients, and Eli Lilly and Genentech, which are developing similar drugs.
The American Geriatrics Society called the panel members’ financial ties to industry “wholly inappropriate.” In an analysis of the proposal, the society warned the proposal could lead to overdiagnosis of Alzheimer’s and subject people to treatments with “limited benefit and high potential for harm.”
Others said the plan was premature at best.
“I think this is untested, uncharted territory,” said Dr. Madhav Thambisetty, a senior researcher at the National Institute of Aging. “I’m not at that stage where I would be able to make a diagnosis of Alzheimer’s disease in somebody who’s cognitively normal based on the presence of a single biomarker.”
A researcher at Washington University in St. Louis works on a blood test for Alzheimer’s disease.
(Huy Mach / University of Washington via Associated Press)
Under the proposal, people with no memory problems who test positive for abnormal levels of amyloid or tau proteins would be classified as Stage 1. They would move to Stage 2 if they begin to experience “neurobehavioral difficulties” such as depression, anxiety or apathy — symptoms often unrelated to Alzheimer’s — even if the patient’s cognition is unchanged.
Stage 3 would be for those with mild cognitive impairment, while Stages 4 through 6 would describe patients with mild, moderate or severe dementia.
The move to label more Americans as having Alzheimer’s comes amid a decades-long decline in the risk of dementia. Researchers don’t know why the risk is falling, but they say higher levels of education, a reduction in smoking and better treatment of high blood pressure could all be factors.
Dr. Peter Whitehouse, professor of neurology at Case Western Reserve University, is one of several doctors who have noted that the plan could benefit the Alzheimer’s Assn. since the majority of its donations come from people who know one of the estimated 6.7 million Americans now living with the disease and want to help find a cure. If more Americans are diagnosed with the disease under the new definition, the ranks of possible donors would swell, he said.
“This raises the potential for more people to want to give money,” Whitehouse added.
The panel said it was proposing the changes now because the FDA has approved two drugs — Eisai’s Leqembi and Aduhelm from Biogen — for patients in the early stages of memory decline. While a study of Leqembi’s effects on asymptomatic people has begun, there is currently no evidence that giving it to people without cognitive impairment can reduce the risk of dementia or delay the onset of Alzheimer’s symptoms.
Another reason for the change, the panel said, was the availability of new blood tests that do an “excellent” job of detecting abnormal levels of amyloid and tau in the brain. The blood tests are easier and less invasive than the PET scans and spinal taps that traditionally have been used to measure levels of Alzheimer’s-related proteins.
“The purpose of this initiative is to advance the science of early detection and treatment,” said panel member Maria Carrillo, the Alzheimer Assn.’s chief science officer. “In order to prevent dementia, we need to detect and treat the disease before symptoms appear.”
Thambisetty and other doctors also note that the plan does not address the serious bioethical concerns that come with testing healthy people for signs of Alzheimer’s.
People with no memory problems who learn they are positive for abnormal levels of amyloid or tau proteins can suffer from depression, anxiety and thoughts of suicide, studies have found.
A doctor points to PET scan results that are part of a study on Alzheimer’s disease at a hospital in Washington.
(Evan Vucci / Associated Press)
A positive test can also lead to discrimination by employers and by companies offering life, disability and long-term care insurance. That risk is so real that people with no memory complaints who volunteer for an ongoing clinical trial that requires an amyloid test are advised to consider getting any insurance they’ve been contemplating before taking the test.
“This is an ethically gray area,” Thambisetty said of testing cognitively normal people. “There are many questions that remain to be answered.”
Added Dr. Eric Widera, a geriatrician at UC San Francisco: “If somebody tests positive for amyloid and they are an airplane pilot, do they have to disclose that to the airlines? They are not asking these questions.”
Concerns like these led the panel members to revise the draft to say they were not yet advocating for “routine” testing of those without memory problems. And Dr. Clifford R. Jack Jr., a radiologist at the Mayo Clinic who leads the panel, told The Times the proposal was not an instruction manual to guide doctors in the evaluation, diagnosis and treatment of their patients.
“Should you diagnose Alzheimer’s disease in asymptomatic persons? The answer is no,” Jack said.
The changes did not reassure skeptics.
Widera pointed out that under the revised plan, an unimpaired person who tests positive for an Alzheimer’s biomarker would not be considered “at risk” for the disease because — in the panel’s view — they already have it.
“They are redefining what it means to have Alzheimer’s,” he said. “You no longer need to have cognitive impairment to have this disease. You just need the positive blood test.”
They are redefining what it means to have Alzheimer’s.
— Dr. Eric Widera, a geriatrician at UC San Francisco
That could lead doctors to prescribe the new drugs to people without memory problems, Widera said.
Indeed, interest in testing for Alzheimer’s-related proteins exploded after the FDA controversially approved Aduhelm and Leqembi, which reduce amyloid levels in the brain.
The hypothesis is that finding amyloid early and removing it might avoid irreversible brain damage. But so far researchers have failed to demonstrate that a build-up of amyloid causes dementia — or that removing it alleviates symptoms.
The FDA went against the advice of its independent advisory committee and green-lighted Biogen’s Aduhelm in 2021 even though there was a lack of evidence that it reduced cognitive decline. A Congressional investigation later found that Biogen executives met with FDA officials — including Dr. Billy Dunn, head of the neuroscience office — dozens of times and inappropriately collaborated on a key regulatory document. Dunn did not respond to questions from The Times.
The FDA approved the second drug, Eisai’s Leqembi, in July after a study showed it could slow the progression of Alzheimer’s in people with mild cognitive impairment by less than half a point on an 18-point scale, a finding that some doctors doubt would be noticeable to patients or their families.
The agency requires both drugs to carry warnings that they can cause potentially fatal bleeding or swelling in the brain.
A closeup of a human brain affected by Alzheimer’s disease is on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y.
(David Duprey / Associated Press)
The Alzheimer’s Assn. has been among the most vocal advocates for the two drugs, which each cost more than $26,000 a year. The group deployed hundreds of volunteers to lobby Congress and get Medicare to pay for the treatments.
While prescriptions of Leqembi are now taking off, doctors have hesitated to prescribe Aduhelm. Last month, Biogen said it planned to stop selling Aduhelm and instead focus on promoting Leqembi through its partnership with Eisai.
The Alzheimer’s Assn.’s plan to create a new class of symptom-free Alzheimer’s patients began taking shape more than a decade ago and was included in proposals to update diagnostic criteria for the disease in 2011 and 2018.
The association’s website says the idea came from a meeting of its Research Roundtable, a group that companies pay thousands of dollars to join. The roundtable meets twice a year, often at the luxury Park Hyatt Hotel in Washington, D.C. Current members include Biogen, Eisai, Lilly, Genentech, Prothena and 15 other companies. Selected academics and drug regulators from around the world are also invited to attend.
In its 2023 fiscal year, the Alzheimer’s Assn. received $4.9 million from pharmaceutical, biotech, diagnostic and clinical research companies — more than in any of the previous five years. The association said those corporate donations amount to just 1.3% of its total cash donations of $379 million that year.
Carrillo, the association’s chief science officer, told The Times in a statement that “no contribution from any organization impacts the Alzheimer’s Association decision-making, nor our positions.”
“We make our decision based on science, and the needs of our constituents,” she said.
The association spent $100 million on research in its 2023 fiscal year, including grants to some of the academic scientists on the panel or to the universities they work for. Many of those grants are aimed at creating new strategies for early diagnosis of people without memory complaints.
That message of early detection is echoed by pharmaceutical and testing companies. At a scientific conference in Boston in October, Dr. Mark Mintun, an Eli Lilly executive who is an advisor to the panel, said in a presentation that the company’s experimental medicine donanemab helped younger people and those with lower levels of tau more than it helped older people and those with higher levels of the protein.
“This gives us great urgency in thinking about how to diagnose and prepare patients for treatment,” Mintun told the audience, according to a report on the Alzforum news website.
Among the seven industry executives sitting on the Alzheimer’s Assn. panel are former FDA official Dunn, who is now on the board of Prothena, a company developing anti-amyloid drugs; Dr. Eric Siemers, chief medical officer of Acumen Pharmaceuticals, which is also working on anti-amyloid drugs; and Dr. Philip Scheltens, who heads a venture capital fund that invests in dementia drugs.
They are joined by Dr. Reisa Sperling, a Harvard neurology professor who has received research grants from Eisai and Lilly and consulting fees from 18 other companies, according to the panel’s disclosures.
Sperling has led studies investigating the value of treating people without memory problems. She said in 2013 that she could see a future where “we will treat everybody preemptively, in the same way we vaccinate.”
Other academic panel members include Charlotte Teunissen, a professor at Amsterdam University Medical Centers who conducts research for 25 companies, and Dr. Michael Rafii, a USC professor of clinical neurology, who disclosed work for 11 companies.
Both Teunissen and Rafii said their industry funding has no bearing on their judgment.
“I believe working with a diverse group of pharmaceutical and biotech companies, each with their own therapeutic approaches and strategies, can mitigate against a single company’s influence,” Rafii said.
Sperling agreed that corporate research funding did not affect her objectivity. “I want to figure out the truth,” she said.
But others are not convinced.
“This panel is dominated by those with financial ties to companies that will directly benefit” from a more expansive view of Alzheimer’s, said Widera of UCSF. “And there was no consideration about the potential downsides or risk to the number of people who are going to be now diagnosed” if its definition is adopted.
The proposal — initially dubbed “The National Institute of Aging–Alzheimer’s Association Revised Criteria for Diagnosing and Staging Alzheimer’s Disease” — has received international attention in part because it seemed to have the backing of one of the U.S. government’s premiere research centers.
The American Geriatrics Society and others said the proposal’s name implied that the NIA, which is part of the National Institutes of Health, was a full partner in the effort.
But Dr. Eliezer Masliah, director of the institute’s neuroscience division, said that while he and another NIA scientist attend panel meetings, they are not involved in its decisions. “We’re listening and recording and just keeping track of the process,” he said.
After The Times asked NIH officials about the NIA’s involvement, they said the institute’s name would be removed from the proposal’s title.
Even before the plan has been finalized, one company told investors it was poised to benefit.
In a November call with Wall Street analysts, Masoud Toloue, the chief executive at Quanterix, pointed out that the company’s blood test for tau — called p-Tau 217 — had been recommended by the panel for diagnosing the disease.
“We believe we’re in a strong position to capitalize on these opportunities,” Toloue said.
Science
In search for autism’s causes, look at genes, not vaccines, researchers say
Earlier this year, Health and Human Services Secretary Robert F. Kennedy Jr. pledged that the search for autism’s cause — a question that has kept researchers busy for the better part of six decades — would be over in just five months.
“By September, we will know what has caused the autism epidemic, and we’ll be able to eliminate those exposures,” Kennedy told President Trump during a Cabinet meeting in April.
That ambitious deadline has come and gone. But researchers and advocates say that Kennedy’s continued fixation on autism’s origins — and his frequent, inaccurate claims that childhood vaccines are somehow involved — is built on fundamental misunderstandings of the complex neurodevelopmental condition.
Even after more than half a century of research, no one yet knows exactly why some people have autistic traits and others do not, or why autism spectrum disorder looks so different across the people who have it. But a few key themes have emerged.
Researchers believe that autism is most likely the result of a complex set of interactions between genes and the environment that unfold while a child is in the womb. It can be passed down through families, or originate with a spontaneous gene mutation.
Environmental influences may indeed play a role in some autism cases, but their effect is heavily influenced by a person’s genes. There is no evidence for a single trigger that causes autism, and certainly not one a child encounters after birth: not a vaccine, a parenting style or a post-circumcision Tylenol.
“The real reason why it’s complicated, the more fundamental one, is that there’s not a single cause,” said Irva Hertz-Picciotto, a professor of public health science and director of the Environmental Health Sciences Center at UC Davis. “It’s not a single cause from one person to the next, and not a single cause within any one person.”
Kennedy, an attorney who has no medical or scientific training, has called research into autism’s genetics a “dead end.” Autism researchers counter that it’s the only logical place to start.
“If we know nothing else, we know that autism is primarily genetic,” said Joe Buxbaum, a molecular neuroscientist who directs the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai. “And you don’t have to actually have the exact genes [identified] to know that something is genetic.”
Some neurodevelopment disorders arise from a difference in a single gene or chromosome. People with Down syndrome have an extra copy of chromosome 21, for example, and Fragile X syndrome results when the FMR1 gene isn’t expressed.
Autism in most cases is polygenetic, which means that multiple genes are involved, with each contributing a little bit to the overall picture.
Researchers have found hundreds of genes that could be associated with autism; there may be many more among the roughly 20,000 in the human genome.
In the meantime, the strongest evidence that autism is genetic comes from studies of twins and other sibling groups, Buxbaum and other researchers said.
The rate of autism in the U.S. general population is about 2.8%, according to a study published last year in the journal Pediatrics. Among children with at least one autistic sibling, it’s 20.2% — about seven times higher than the general population, the study found.
Twin studies reinforce the point. Both identical and fraternal twins develop in the same womb and are usually raised in similar circumstances in the same household. The difference is genetic: identical twins share 100% of their genetic information, while fraternal twins share about 50% (the same as nontwin siblings).
If one fraternal twin is autistic, the chance that the other twin is also autistic is about 20%, or about the same as it would be for a nontwin sibling.
But if one in a pair of identical twins is autistic, the chance that the other twin is also autistic is significantly higher. Studies have pegged the identical twin concurrence rate anywhere from 60% to 90%, though the intensity of the twins’ autistic traits may differ significantly.
Molecular genetic studies, which look at the genetic information shared between siblings and other blood relatives, have found similar rates of genetic influence on autism, said Dr. John Constantino, a professor of pediatrics, psychiatry and behavioral sciences at the Emory University School of Medicine and chief of behavioral and mental health at Children’s Healthcare of Atlanta.
Together, he said, “those studies have indicated that a vast share of the causation of autism can be traced to the effects of genetic influences. That is a fact.”
Buxbaum compares the heritability of autism to the heritability of height, another polygenic trait.
“There’s not one gene that’s making you taller or shorter,” Buxbaum said. Hundreds of genes play a role in where you land on the height distribution curve. A lot of those genes run in families — it’s not unusual for very tall people, for example, to have very tall relatives.
But parents pass on a random mix of their genes to their children, and height distribution across a group of same-sex siblings can vary widely. Genetic mutations can change the picture. Marfan syndrome, a condition caused by mutations in the FBN1 gene, typically makes people grow taller than average. Hundreds of genetic mutations are associated with dwarfism, which causes shorter stature.
Then once a child is born, external factors such as malnutrition or disease can affect the likelihood that they reach their full height potential.
So genes are important. But the environment — which in developmental science means pretty much anything that isn’t genetics, including parental age, nutrition, air pollution and viruses — can play a major role in how those genes are expressed.
“Genetics does not operate in a vacuum, and at the same time, the impact of the environment on people is going to depend on a person’s individual genetics,” said Brian K. Lee, a professor of epidemiology and biostatistics at Drexel University who studies the genetics of developmental disorders.
Unlike the childhood circumstances that can affect height, the environmental exposures associated with autism for the most part take place in utero.
Researchers have identified multiple factors linked to increased risks of the disorder, including older parental age, infant prematurity and parental exposure to air pollution and industrial solvents.
Investigations into some of these linkages were among the more than 50 autism-related studies whose funding Kennedy has cut since taking office, a ProPublica investigation found. In contrast, no credible study has found links between vaccines and autism — and there have been many.
One move from the Department of Health and Human Services has been met with cautious optimism: even as Kennedy slashed funding to other research projects, the department in September announced a $50-million initiative to explore the interactions of genes and environmental factors in autism, which has been divided among 13 different research groups at U.S. universities, including UCLA and UC San Diego.
The department’s selection of well-established, legitimate research teams was met with relief by many autism scientists.
But many say they fear that such decisions will be an anomaly under Kennedy, who has repeatedly rejected facts that don’t conform to his preferred hypotheses, elevated shoddy science and muddied public health messaging on autism with inaccurate information.
Disagreements are an essential part of scientific inquiry. But the productive ones take place in a universe of shared facts and build on established evidence.
And when determining how to spend limited resources, researchers say, making evidence-based decisions is vital.
“There are two aspects of these decisions: Is it a reasonable expenditure based on what we already know? And if you spend money here, will you be taking money away from HHS that people are in desperate need of?” Constantino said. “If you’re going to be spending money, you want to do that in a way that is not discarding what we already know.”
Science
Contributor: New mothers are tempted by Ozempic but don’t have the data they need
My friend Sara, eight weeks after giving birth, left me a tearful voicemail. I’m a clinical psychologist specializing in postpartum depression and psychosis, but mental health wasn’t Sara’s issue. Postpartum weight gain was.
Sara told me she needed help. She’d gained 40 pounds during her pregnancy, and she was still 25 pounds overweight. “I’m going back to work and I can’t look like this,” she said. “I need to take Ozempic or something. But do you know if it’s safe?”
Great question. Unfortunately researchers don’t yet have an answer. On Dec. 1, the World Health Organization released its first guidelines on the use of GLP-1 receptor agonists such as Ozempic, generically known as semaglutide. One of the notable policy suggestions in that report is to not prescribe GLP-1s to pregnant women. Disappointingly, the report says nothing about the use of the drug by postpartum women, including those who are breastfeeding.
There was a recent Danish study that led to medical guidelines against prescribing to patients who are pregnant or breastfeeding.
None of that is what my friend wanted to hear. I could only encourage her to speak to her own medical doctor.
Sara’s not alone. I’ve seen a trend emerging in my practice in which women use GLP-1s to shed postpartum weight. The warp speed “bounce-back” ideal of body shapes for new mothers has reemerged, despite the mental health field’s advocacy to abolish the archaic pressure of martyrdom in motherhood. GLP-1s are being sold and distributed by compound pharmacies like candy. And judging by their popularity, nothing tastes sweeter than skinny feels.
New motherhood can be a stressful time for bodies and minds, but nature has also set us up for incredible growth at that moment. Contrary to the myth of spaced-out “mommy brains,” new neuroplasticity research shows that maternal brains are rewired for immense creativity and problem solving.
How could GLP-1s affect that dynamic? We just don’t know. We do know that these drugs are associated with changes far beyond weight loss, potentially including psychiatric effects such as combating addiction.
Aside from physical effects, this points to an important unanswered research question: What effects, if any, do GLP-1s have on a woman’s brain as it is rewiring to attune to and take care of a newborn? And on a breastfeeding infant? If GLP-1s work on the pleasure center of the brain and your brain is rewiring to feel immense pleasure from a baby coo, I can’t help but wonder if that will be dampened. When a new mom wants a prescription for a GLP-1 to help shed baby weight, her medical provider should emphasize those unknowns.
These drugs may someday be a useful tool for new mothers. GLP-1s are helping many people with conditions other than obesity. A colleague of mine was born with high blood pressure and cholesterol. She exercised every day and adopted a pescatarian diet. Nothing budged until she added a GLP-1 to her regimen, bringing her blood pressure to a healthy 120/80 and getting cholesterol under control. My brother, an otherwise healthy young man recently diagnosed with a rare idiopathic lymphedema of his left leg, is considering GLP-1s to address inflammation and could be given another chance at improving his quality of life.
I hope that GLP-1s will continue to help those who need it. And I urge everyone — especially new moms — to proceed with caution. A healthy appetite for nutritious food is natural. That food fuels us for walks with our dogs, swims along a coastline, climbs through leafy woods. It models health and balance for the young ones who are watching us for clues about how to live a healthy life.
Nicole Amoyal Pensak, a clinical psychologist and researcher, is the author of “Rattled: How to Calm New Mom Anxiety With the Power of the Postpartum Brain.”
Science
California issues advisory on a parasitic fly whose maggots can infest living humans
A parasitic fly whose maggots can infest living livestock, birds, pets and humans could threaten California soon.
The New World Screwworm has rapidly spread northward from Panama since 2023 and farther into Central America. As of early September, the parasitic fly was present in seven states in southern Mexico, where 720 humans have been infested and six of them have died. More than 111,000 animals also have been infested, health officials said.
In early August, a person traveling from El Salvador to Maryland was discovered to have been infested, federal officials said. But the parasitic fly has not been found in the wild within a 20-mile radius of the infested person, which includes Maryland, Virginia and the District of Columbia.
After the Maryland incident, the California Department of Public Health decided to issue a health advisory this month warning that the New World Screwworm could arrive in California from an infested traveler or animal, or from the natural travel of the flies.
Graphic images of New World Screwworm infestations show open wounds in cows, deer, pigs, chickens, horses and goats, infesting a wide swath of the body from the neck, head and mouth to the belly and legs.
The Latin species name of the fly — hominivorax — loosely translates to “maneater.”
“People have to be aware of it,” said Dr. Peter Chin-Hong, a UC San Francisco infectious diseases specialist. “As the New World Screwworm flies northward, they may start to see people at the borders — through the cattle industry — get them, too.”
Other people at higher risk include those living in rural areas where there’s an outbreak, anyone with open sores or wounds, those who are immunocompromised, the very young and very old, and people who are malnourished, the U.S. Centers for Disease Control and Prevention says.
There could be grave economic consequences should the New World Screwworm get out of hand among U.S. livestock, leading to animal deaths, decreased livestock production, and decreased availability of manure and draught animals, according to the U.S. Department of Agriculture.
“It is not only a threat to our ranching community — but it is a threat to our food supply and our national security,” the USDA said.
Already, in May, the USDA suspended imports of live cattle, horse and bison from the Mexican border because of the parasitic fly’s spread through southern Mexico.
The New World Screwworm isn’t new to the U.S.
But it was considered eradicated in the United States in 1966, and by 1996, the economic benefit of that eradication was estimated at nearly $800 million, “with an estimated $2.8 billion benefit to the wider economy,” the USDA said.
Texas suffered an outbreak in 1976. A repeat could cost the state’s livestock producers $732 million a year and the state economy $1.8 billion, the USDA said.
Historically, the New World Screwworm was a problem in the U.S. Southwest and expanded to the Southeast in the 1930s after a shipment of infested animals, the USDA said. Scientists in the 1950s discovered a technique that uses radiation to sterilize male parasitic flies.
Female flies that mate with the sterile male flies produce sterile eggs, “so they can’t propagate anymore,” Chin-Hong said. It was this technique that allowed the U.S., Mexico and Central America to eradicate the New World Screwworm by the 1960s.
But the parasitic fly has remained endemic in South America, Cuba, Haiti and the Dominican Republic.
In late August, the USDA said it would invest in new technology to try to accelerate the pace of sterile fly production. The agency also said it would build a sterile-fly production facility at Edinburg, Texas, which is close to the Mexico border, and would be able to produce up to 300 million sterile flies per week.
“This will be the only United States-based sterile fly facility and will work in tandem with facilities in Panama and Mexico to help eradicate the pest and protect American agriculture,” the USDA said.
The USDA is already releasing sterile flies in southern Mexico and Central America.
The risk to humans from the fly, particularly in the U.S., is relatively low. “We have decent nutrition; people have access to medical care,” Chin-Hong said.
But infestations can happen. Open wounds are a danger, and mucus membranes can also be infested, such as inside the nose, according to the CDC.
An infestation occurs when fly maggots infest the living flesh of warm-blooded animals, the CDC says. The flies “land on the eyes or the nose or the mouth,” Chin-Hong said, or, according to the CDC, in an opening such as the genitals or a wound as small as an insect bite. A single female fly can lay 200 to 300 eggs at a time.
When they hatch, the maggots — which are called screwworms — “have these little sharp teeth or hooks in their mouths, and they chomp away at the flesh and burrow,” Chin-Hong said. After feeding for about seven days, a maggot will fall to the ground, dig into the soil and then awaken as an adult fly.
Deaths among humans are uncommon but can happen, Chin-Hong said. Infestation should be treated as soon as possible. Symptoms can include painful skin sores or wounds that may not heal, the feeling of the larvae moving, or a foul-smelling odor, the CDC says.
Patients are treated by removal of the maggots, which need to be killed by putting them into a sealed container of concentrated ethyl or isopropyl alcohol then disposed of as biohazardous waste.
The parasitic fly has been found recently in seven Mexican states: Campeche, Chiapas, Oaxaca, Quintana Roo, Tabasco, Veracruz, and Yucatán. Officials urge travelers to keep open wounds clean and covered, avoid insect bites, and wear hats, loose-fitting long-sleeved shirts and pants, socks, and insect repellents registered by the Environmental Protection Agency as effective.
-
Alaska6 days agoHowling Mat-Su winds leave thousands without power
-
Politics1 week agoTrump rips Somali community as federal agents reportedly eye Minnesota enforcement sweep
-
Ohio1 week ago
Who do the Ohio State Buckeyes hire as the next offensive coordinator?
-
Texas6 days agoTexas Tech football vs BYU live updates, start time, TV channel for Big 12 title
-
News1 week agoTrump threatens strikes on any country he claims makes drugs for US
-
World1 week agoHonduras election council member accuses colleague of ‘intimidation’
-
Washington3 days agoLIVE UPDATES: Mudslide, road closures across Western Washington
-
Iowa5 days agoMatt Campbell reportedly bringing longtime Iowa State staffer to Penn State as 1st hire